Hope in the fight against ALS
The Community of Madrid is at the forefront of medical research with the launch of a clinical trial that promises to revolutionise the treatment of amyotrophic lateral sclerosis (ALS). This innovative study, which will begin in April at the Hospital Universitario de La Princesa, focuses on the drug AP-2, designed to directly target the underlying causes of this devastating disease.
Under the direction of Dr Dolores Ochoa, the principal investigator of the project, the trial aims to address a critical aspect of ALS: the pathological alteration of the TDP-43 protein. This protein is essential for the proper functioning of motor neurons, and its dysfunction is associated with the cell death that characterises this disease. According to Ochoa, the drug AP-2 has shown promising results in reversing these alterations in both cellular models and transgenic animals.
Despite medical advances, the treatments available for ALS patients have been limited and mostly palliative. So far, there is only one approved medication that offers minimal benefits, prolonging the patient's life by a few months without significantly improving their functional quality. In contrast, Ochoa highlights that AP-2 has demonstrated not only neuroprotection but also a remarkable reduction in inflammation, which could translate into a slowing or even halting of the disease's progression.
The clinical trial has been authorised by the Spanish Agency for Medicines and Health Products (Aemps), and will be conducted in several phases to ensure the safety and efficacy of the treatment:
- April 2026: Start of the study with healthy volunteers to assess initial safety.
- End of 2026: Preliminary results from the first human trial.
- January 2027: Start of the study with patients diagnosed with ALS.
The response to this announcement has been overwhelming; numerous patients and families have expressed their interest in participating. Dr Ochoa mentions that they have received multiple inquiries since this initiative was made public, reflecting great hope among those facing this devastating disease.
You may also like
